Claims

1. A pharmaceutical composition comprising 15 µg recombinant follicle stimulating hormone (rFSH), wherein the rFSH includes α2,6-sialylation and α2,3-sialylation wherein 11 % to 15% of the total sialylation is α2, 6-sialyation, and 85% to 89% of the total sialylation is α 2,3-sialyation and the rFSH is the sole active pharmaceutical ingredient in the composition.